


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: WSTR-0017B
Inventors: Gerhard et al.
Serial No.: 10/757,692
Filing Date: January 14, 2004
Examiner: Not Yet Assigned
Group Art Unit: 1648
Title: Composition and Method for Preventing or
Treating a Virus Infection

I, Kathleen A. Tyrrell, Registration No. 38,350,
certify that this correspondence is being deposited
with the U.S. Postal Service as First Class mail in
an envelope addressed to the Commissioner for Patents
P.O. Box 1450, Alexandria, VA 22313-1450

On this date: June 8, 2004


Kathleen A. Tyrrell, Registration No. 38,350

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

(XX) In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified

application, within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, no additional fee is required.

() In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, therefore:

() Certification in Accordance with §1.97(e) is attached hereto; or

() Authorization to charge Deposit Account No. 50-1616 the fee of \$180.00 as set forth in §1.17(p) is provided.

() In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee, therefore included are: Certification in Accordance with §1.97(e); Petition Requesting Consideration of the Information Disclosure Statement; and the fee of \$130.00 as set forth in §1.17(I) (1).

(XX) Copies of each of the references listed on the attached Form PTO-1449 (modified) are enclosed herewith.


() In accordance with §1.98(d), copies of some or all of the references listed on the attached Form PTO-1449 (modified) are not enclosed herewith because they were previously submitted to the U.S. Patent and Trademark Office in prior application Serial No. _____, filed _____, for which a claim for priority under 35 U.S.C. §120 has been made in the instant application.

Please charge any deficiency or credit any overpayment to Deposit Account No. 50-1619. This form is submitted in duplicate.

() The relevance of the listed references in a foreign language is as stated in the specification at pages @@.

(XX) All listed references are in the English language.

Respectfully submitted,



Kathleen A. Tyrrell
Registration No. 38,350

Date: June 8, 2004

Licata & Tyrrell P.C.
66 E. Main Street
Marlton, New Jersey 08053

(856) 810-1515



Form PTO-1449 Modified List of Patents and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce	Docket No. WSTR-0017B	Serial No. 10/757,692
	Applicant Gerhard et al.	
	Filing Date January 14, 2004	Group 1648

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	AA	Falugi et al., "Rationally designed strings of promiscuous CD4 ⁺ T cell epitopes provide help to <i>Haemophilus influenzae</i> type b oligosaccharide: a model for new conjugate vaccines", Eur. J. Immunol. 2001 31:3816-3824
	AB	Fiers et al., "Soluble recombinant influenza vaccines", Phil. Trans. R. Soc. Lond. B 2001 356:1961-1963
	AC	Gerhard et al., "Identification of Eight Determinants in the Hemagglutinin Molecule of Influenza Virus A/PR/8/34 (H1N1) Which Are Recognized by Class II-Restricted T Cells from BALB/c Mice", J. Virology 1991 65(1):364-372
	AD	Heinen et al., "Vaccination of pigs with a DNA construct expressing an influenza virus M2-nucleoprotein fusion protein exacerbates disease after challenge with influenza A virus", J. General Virology 2002 83:1851-1859
	AE	Neirynck et al., "A universal influenza A vaccine based on the extracellular domain of the M2 protein", Nature Medicine 1999 5(10):1157-1163
	AF	Zaliauskiene et al., "Enhancement of MHC Class II-Restricted Responses by Receptor-Mediated Uptake of Peptide Antigens ¹ ", J. Immunol 2002 169:2337-2345

EXAMINER	DATE CONSIDERED
-----------------	------------------------